Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront

Voyager Therapeutics, Inc.

2022-Q1 EPS reported -$0.56 revenue$658,000

Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.
Novartis license option: $54M upfront, up to $1.5B milestones for TRACER capsids on up to 5 CNS targets.
Alfred Sandrock appointed CEO (March 2022); Robin Swartz promoted to COO.
TRACER AAV9 capsid yields 50-60x better brain transduction in mice/macaques vs AAV9; AAV5 capsid 20x vs AAV9.
Preclinical data: vectorized HER2 antibody reduces tumor burden; GBA1, SOD1, anti-tau programs advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.